Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab, Palbociclib, and Cetuximab in R/M HNSCC
NCT03498378Phase 1Active, not recruiting
- Start
- Jun 2018
- Primary completion
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avelumab and palbociclib in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Maximum Tolerated Dose at 12 months. Started Jun 2018; status: active, not recruiting.
02
Drugs
avelumabpalbociclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03498378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498378.